Swiss health insurers decide case by case whether to cover medicines outside routine reimbursement. These include drugs prescribed for an unapproved use and drugs that are approved but absent from the list of routinely reimbursed medicines. An evaluation commissioned by the Federal Office of Public Health (FOPH) estimated that about 38,000 new requests were submitted in 2019. Roughly half were cancer drugs. Just under 80% were approved overall.

The evaluation, published in December 2020, found wide differences between insurers. The authors cautioned that companies recorded requests differently. Some counted a trial of treatment as an approval, while others counted it as a refusal. Even within one group of insurers that recorded requests in the same way, approval rates ranged from 46% to 74%. However, the report did not give the names of health insurers, instead choosing to anonymise them.
SRF sought the underlying data under Switzerland’s freedom-of-information law and obtained them after a five-year legal battle. This week, it published a ranking showing the names of the insurers.
How often Swiss insurers agreed to cover individual treatments
The chart above shows recorded approval rates from March 1st 2017 to December 31st 2019, calculated by SRF from FOPH data. The ranking includes insurers with at least 300 requests. Insurers differed in how they recorded treatment trials.
Sanitas disputed the comparison. It says it now allows either a treatment or a trial of treatment in about 80% of requests. Prio Swiss, an industry association, said differences in how insurers recorded requests made direct comparisons difficult. It also acknowledged that the evaluation found differences among insurers that recorded requests in comparable ways.
The researchers also asked several insurers to assess the same hypothetical request. Some agreed to pay, some proposed a trial of treatment and others refused. The authors attributed most of the variation in that exercise to differences in medical advisers’ assessments. The advisers evaluate the expected therapeutic benefit and make a recommendation. The insurer decides whether to pay and may negotiate the price.
A reform that took effect on January 1st 2024 standardised aspects of how insurers assess treatments and set reimbursement prices. Prio Swiss says comparable recent data are needed to establish how much the gaps have narrowed.
For more stories like this on Switzerland follow us on Facebook and X.

Leave a Reply